V. Chu

发表

Pharmacodynamic markers in the early clinical assessment of otamixaban, a direct factor Xa inhibitor

A. Paccaly, G. Freyburger, M. Ozoux, 2005, Thrombosis and Haemostasis.

Chido and Rogers antigenic determinant on the fourth component of human complement.

I. Gigli, W. Marsh, V. Chu, 1982, Journal of immunology.

Pharmacological characterization of a novel factor Xa inhibitor, FXV673.

C. Dunwiddie, R. Bentley, D. Colussi, 2001, Thrombosis research.

In vitro characterization of a novel factor Xa inhibitor, RPR 130737.

C. Dunwiddie, A. Spada, D. Colussi, 2000, Thrombosis research.

Anti-thrombotic activity of RG13965, a novel platelet fibrinogen receptor antagonist.

C. Dunwiddie, J. Cook, J. Bostwick, 1996, Thrombosis research.

Antithrombotic activity of a linear conformationally flexible RGD mimic

Z. Ruggeri, J. Cook, J. Bostwick, 1993 .

Novel RGD analogs as antithrombotic agents

J. Newman, J. Barrett, Z. Ruggeri, 1991 .

Optimization of the beta-aminoester class of factor Xa inhibitors. Part 1: P(4) and side-chain modifications for improved in vitro potency.

C. Dunwiddie, D. Cheney, A. Spada, 2002, Bioorganic & medicinal chemistry letters.

Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis

R. Bentley, S. Rebello, R. Leadley, 2001, British journal of pharmacology.

Role of Short‐Term Inhibition of Factor Xa by FXV673 in Arterial Passivation: A Study in a Chronic Model of Thrombosis in Conscious Dogs

Wei Wang, R. Bentley, D. Colussi, 2001, Journal of cardiovascular pharmacology.

Constrained β-alanine based GpIIb/IIIa antagonists

S. Klein, V. Chu, B. F. Molino, 1997 .

Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis.

R. Bentley, D. Colussi, J. Bostwick, 2000, European journal of pharmacology.

Superiority of enoxaparin over heparin in combination with a GPIIb/IIIa receptor antagonist during coronary thrombolysis in dogs.

R. Bentley, S. Rebello, J. Bostwick, 2001, Thrombosis research.

Design of a new class of orally active fibrinogen receptor antagonists.

C. Dunwiddie, R. Bentley, J. Bostwick, 1998, Journal of medicinal chemistry.

Pharmacokinetic/Pharmacodynamic Relationships for Otamixaban, a Direct Factor Xa Inhibitor, in Healthy Subjects

A. Frick, R. Rosenburg, B. Jensen, 2006, Journal of clinical pharmacology.

Conformationally flexible platelet aggregation inhibitors based on the tetrapeptide Arg-Gly-Asp-Arg

S. Klein, V. Chu, B. F. Molino, 1997 .

Non-peptide fibrinogen receptor antagonists based upon a 4-substituted piperidine scaffold

C. Dunwiddie, R. Leadley, S. Klein, 1996 .

Pharmacodynamic activity and antithrombotic efficacy of RPR120844, a novel inhibitor of coagulation factor Xa.

C. Dunwiddie, R. Bentley, A. Spada, 1999, Journal of cardiovascular pharmacology.

RPR120844, a Novel, Specific Inhibitor of Coagulation Factor Xa Inhibits Venous Thrombosis in the Rabbit

C. Dunwiddie, R. Bentley, A. Spada, 1999, Thrombosis and Haemostasis.

Amido-(propyl and allyl)-hydroxybenzamidines: development of achiral inhibitors of factor Xa.

A. Spada, D. Colussi, Y. Gong, 2000, Bioorganic & medicinal chemistry letters.

Discovery of an orally efficacious inhibitor of coagulation factor Xa which incorporates a neutral P1 ligand.

Robert Leadley, Guyan Liang, R. Bentley, 2003, Journal of medicinal chemistry.

Aminoisoquinolines: design and synthesis of an orally active benzamidine isostere for the inhibition of factor XA.

C. Dunwiddie, D. Cheney, R. Bentley, 1999, Bioorganic & medicinal chemistry letters.

Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa.

D L Cheney, C. Dunwiddie, J. Mason, 1999, Journal of medicinal chemistry.

Nonbenzamidine compounds as selective factor Xa inhibitors.

M. Myers, A. Spada, D. Colussi, 2000, Bioorganic & medicinal chemistry letters.

Synthesis, SAR and in vivo activity of novel thienopyridine sulfonamide pyrrolidinones as factor Xa inhibitors.

R. Bentley, A. Spada, C. Ly, 1999, Bioorganic & medicinal chemistry letters.

Benzimidazoles and isosteric compounds as potent and selective factor Xa inhibitors.

M. Myers, Wei He, A. Spada, 2002, Bioorganic & Medicinal Chemistry Letters.

Solid-phase parallel synthesis of azarene pyrrolidinones as factor Xa inhibitors.

J. Salvino, Y. M. Choi-Sledeski, Y. Gong, 2000, Bioorganic & medicinal chemistry letters.

Identification and initial structure-activity relationships of a novel class of nonpeptide inhibitors of blood coagulation factor Xa.

D L Cheney, C. Dunwiddie, D. Cheney, 1998, Journal of medicinal chemistry.

Sulfonamidopyrrolidinone factor Xa inhibitors: potency and selectivity enhancements via P-1 and P-4 optimization.

C. Dunwiddie, D. Cheney, R. Bentley, 1999, Journal of medicinal chemistry.

In Vitro and in Vivo Induction of Cytochrome P450: A Survey of the Current Practices and Recommendations: A Pharmaceutical Research and Manufacturers of America Perspective

Vikram Sinha, Heidi J Einolf, Michael Sinz, 2009, Drug Metabolism and Disposition.

Optimization of a Recombinant von Willebrand Factor Fragment as an Antagonist of the Platelet Glycoprotein Ib Receptor

B. Cambou, J. Ware, G. Searfoss, 1993, Bio/Technology.

Production and Functional Characterization of a Recombinant Fragment of Von Willebrand Factor (vWF): An Antagonist to Platelet Receptor Gp Ib

G. Ricca, C. Prior, J. Holt, 1992, Bio/Technology.

In Vitro and In Vivo Induction of Cytochrome P 450 : A Survey of the Current Practices and Recommendations : A Pharmaceutical Research and Manufacturers of America ( PhRMA ) Perspective

R. Evers, V. Sinha, D. Moore, 2009 .

Platelet Aggregation on Extracellular Matrix: Effect of a Recombinant GPIb-Binding Fragment of von Willebrand Factor

U. Martinowitz, N. Savion, Z. Ruggeri, 1993, Thrombosis and Haemostasis.

Benzimidazoles and Isosteric Compounds as Potent and Selective Factor Xa Inhibitors

M. Myers, Wei He, A. Spada, 2002 .

Optimization of the beta-aminoester class of factor Xa inhibitors. Part 2: Identification of FXV673 as a potent and selective inhibitor with excellent In vivo anticoagulant activity.

Daniel L Cheney, C. Dunwiddie, D. Cheney, 2002, Bioorganic & medicinal chemistry letters.